Aptorum.

Company Overview.

Aptorum Group Limited (Nasdaq: APM) is a biopharmaceutical company dedicated to developing and commercializing novel therapeutics to tackle unmet medical needs. Aptorum Group is pursuing therapeutic projects in neurology, infectious diseases, gastroenterology, oncology and other disease areas.

Its principal office in Asia provides easy access to prosperous medical research resources and some of the world’s most talented specialists and clinicians. We have established strong relationships and collaborations with leading academic institutions to propel therapeutic innovations.

To date, Aptorum has obtained 11 exclusively licensed technologies in the areas of neurology, infectious diseases, gastroenterology, oncology, surgical robotics and natural health.

Is APM a good pick?

APM in the last 5 years has been improving its financial health, in 2020 they had profits over 100% compared to 2019. The company is based in Europe but China is its best customer where in the coming years it seeks to position itself strongly, hand in hand with its pharmaceutical projects such as the new drug that seeks to eradicate neuroblastoma that was recently approved by the FDA. The company has not yet released its annual report for 2021 but it is expected to increase its profits by more than 20%.

Technical Analysis.

From July 2021 the stock has been in a downtrend, during the last 25 weeks the price has oscillated between $2.87 and $1.17, whereas January 19 took the 25 week low over $1.17, At the present time, the price is $1.48

The price of the stock in the last month had a loss of 40%, then revalued by 46% in a sudden rise on January 20, we see that the price touched SMA50, and it could not break it and stopped its rise.

Looking at our indicators we obtain that the RSI has remained in the last two months in an oversold zone, MACD has also been below its signal and after the sudden rise of last week it took strength to cross its signal

What happened last January 20?

The FDA cleared a new drug for APM, which seeks to eradicate neuroblastoma. Following the news the stock had a strong 46% revaluation, the company indicated that it will now move into the testing phase and is looking to bring out this new product in 2023.

Considering all that is mentioned, it is probable that the price will go up at least 36% until the first Fibonacci resistor, which is at $1.66.